Salarius Pharmaceuticals, Inc. 8-K

What Happened

• Salarius Pharmaceuticals, Inc. (SLRX) announced by Form 8-K (filed Dec 19, 2025) that its 2025 annual meeting of stockholders was convened on Dec 19, 2025 but adjourned because there was not a sufficient number of shares present or represented by proxy to constitute a quorum.
• The company said the meeting will reconvene virtually on December 31, 2025 at 10:00 am Central Time via live webcast at www.virtualshareholdermeeting.com/SLRX2025. No changes have been made to the proposals described in the Definitive Proxy Statement filed Nov 7, 2025.

Key Details

• Adjournment date: December 19, 2025 (meeting lacked quorum).
• Reconvened meeting: December 31, 2025 at 10:00 am CT (virtual webcast).
• Record date for eligibility to vote remains October 24, 2025.
• Proxies previously submitted will be voted at the reconvened meeting unless properly revoked; stockholders who already submitted a proxy do not need to take action.

Why It Matters

• The adjournment delays the formal vote on the proposals set forth in the company’s Definitive Proxy Statement (e.g., director elections or other matters listed there) until the reconvened meeting.
• Investors should note the reconvened meeting date/time and that previously submitted proxies remain valid; review the Definitive Proxy Statement and related proxy materials (available on SEC.gov) if you plan to vote or change your proxy.
• The company also issued a press release about the adjournment and reconvening (furnished as Exhibit 99.1), disclosed under Regulation FD in the 8-K.